Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after progression on bevacizumab with oxaliplatine-based chemotherapy in patients with metastatic colorectal cancer whose KRAS status are investigated.
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2619669
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Treatment is administered every 2 weeks until evidence of progression, unacceptable toxicity or patient refusal. During the treatment, image assessment is repeated every 2 months at least.
Primary outcome(s): Overall response rate
Study Design: Single arm Non-randomized
创建时间：
2010-02-15
